C Michael Gibson Selected Research

MB Form Creatine Kinase

4/2016	EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention.
1/2016	Relation of Left Ventricular Mass and Infarct Size in Anterior Wall ST-Segment Elevation Acute Myocardial Infarction (from the EMBRACE STEMI Clinical Trial).
10/2015	The effect of rivaroxaban on myocardial infarction in the ATLAS ACS 2 - TIMI 51 trial.
3/2015	Utility of peak creatine kinase-MB measurements in predicting myocardial infarct size, left ventricular dysfunction, and outcome after first anterior wall acute myocardial infarction (from the INFUSE-AMI trial).
4/2013	Rationale and design of the EMBRACE STEMI study: a phase 2a, randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability and efficacy of intravenous Bendavia on reperfusion injury in patients treated with standard therapy including primary percutaneous coronary intervention and stenting for ST-segment elevation myocardial infarction.
4/2009	Incidence, distribution, and prognostic impact of occluded culprit arteries among patients with non-ST-elevation acute coronary syndromes undergoing diagnostic angiography.
2/2008	Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction.
7/2002	The prognostic value of serum myoglobin in patients with non-ST-segment elevation acute coronary syndromes. Results from the TIMI 11B and TACTICS-TIMI 18 studies.
1/2002	Relationship of creatine kinase-myocardial band release to Thrombolysis in Myocardial Infarction perfusion grade after intracoronary stent placement: an ESPRIT substudy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

C Michael Gibson Research Topics

Disease

220	Myocardial Infarction 11/2022 - 01/2002
139	Hemorrhage 12/2022 - 02/2002
131	ST Elevation Myocardial Infarction 06/2022 - 03/2002
100	Thrombosis (Thrombus) 11/2022 - 07/2002
100	Acute Coronary Syndrome 06/2022 - 04/2002
51	Infarction (Infarctions) 01/2022 - 01/2002
45	Ischemia 03/2022 - 02/2002
33	Stroke (Strokes) 03/2022 - 09/2005
31	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 04/2002
27	Heart Failure 01/2021 - 03/2002
24	Atrial Fibrillation 01/2021 - 05/2005
23	Unstable Angina 05/2017 - 02/2002
19	Venous Thromboembolism 02/2020 - 03/2014
16	Non-ST Elevated Myocardial Infarction 11/2020 - 11/2002
11	Pathologic Constriction (Stenosis) 01/2016 - 02/2002
10	Coronary Artery Disease (Coronary Atherosclerosis) 01/2021 - 11/2002
10	Intracranial Hemorrhages (Intracranial Hemorrhage) 01/2020 - 04/2003
9	Inflammation (Inflammations) 06/2022 - 02/2003
9	Death (Near-Death Experience) 11/2020 - 11/2013
8	Pulmonary Embolism 11/2020 - 05/2005
8	Diabetes Mellitus 01/2020 - 10/2002
8	Venous Thrombosis (Deep-Vein Thrombosis) 12/2018 - 01/2015
7	COVID-19 01/2022 - 01/2020
7	Atherosclerosis 01/2022 - 02/2003
6	Stable Angina 11/2018 - 08/2004
6	Hypertension (High Blood Pressure) 01/2014 - 02/2003
5	Necrosis 06/2022 - 05/2005
5	Chest Pain (Chest Pains) 01/2020 - 05/2002
5	Renal Insufficiency (Renal Failure) 01/2020 - 02/2003
4	Rupture 01/2022 - 06/2003
4	Infections 12/2021 - 10/2005
4	Chronic Renal Insufficiency 12/2021 - 06/2014
4	Shock 01/2021 - 06/2002
4	Reperfusion Injury 12/2019 - 04/2013

Drug/Important Bio-Agent (IBA)

58	Clopidogrel (Plavix)FDA Link 01/2022 - 08/2004
38	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 03/2022 - 12/2002
35	Glycoproteins (Glycoprotein)IBA 08/2021 - 11/2002
29	cangrelorIBA 03/2022 - 12/2009
27	Enoxaparin (Lovenox)FDA LinkGeneric 02/2020 - 04/2002
26	Biomarkers (Surrogate Marker)IBA 06/2022 - 04/2002
25	2'- deoxythymidylyl- (3'- 5')- 2'- deoxyadenosine (d(AT))IBA 12/2022 - 07/2013
25	RivaroxabanIBA 11/2019 - 05/2011
23	N(2)-(3-trifluoromethylphenyl)guanineIBA 06/2022 - 01/2002
21	Abciximab (ReoPro)FDA Link 10/2016 - 07/2003
21	Eptifibatide (Integrilin)FDA Link 04/2014 - 04/2003
19	omega-Chloroacetophenone (Mace)IBA 11/2020 - 02/2009
19	Heparin (Liquaemin)FDA LinkGeneric 07/2020 - 12/2002
19	Tirofiban (Aggrastat)FDA Link 01/2012 - 07/2002
18	AnticoagulantsIBA 01/2021 - 03/2005
17	Fibrinolytic Agents (Antithrombotic Agents)IBA 07/2020 - 10/2002
17	betrixabanIBA 02/2020 - 03/2014
16	TicagrelorIBA 03/2022 - 07/2013
16	Pharmaceutical PreparationsIBA 01/2022 - 03/2002
16	bivalirudin (Angiomax)FDA Link 01/2017 - 05/2006
15	Vitamin K FDA Link 01/2021 - 06/2012
13	Tenecteplase FDA Link 01/2020 - 04/2003
11	TroponinIBA 01/2020 - 07/2002
11	AntithrombinsIBA 01/2020 - 04/2002
10	C-Reactive ProteinIBA 06/2022 - 04/2002
10	S- (2- chloro- 1,1,2- trifluoroethyl)cysteine (CTFC)IBA 01/2020 - 04/2002
10	fibrin fragment D (D-dimer)IBA 01/2020 - 01/2015
9	Brain Natriuretic Peptide (Natrecor)FDA Link 06/2022 - 04/2002
9	Thrombin FDA Link 01/2020 - 06/2006
9	MB Form Creatine KinaseIBA 04/2016 - 01/2002
8	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2022 - 10/2005
8	Factor Xa InhibitorsIBA 03/2019 - 05/2011
8	Prasugrel Hydrochloride FDA Link 01/2019 - 10/2006
8	GadoliniumIBA 08/2014 - 01/2006
7	CreatinineIBA 01/2019 - 11/2003
7	Tissue Plasminogen Activator (Alteplase)FDA Link 01/2018 - 05/2003
7	Platelet Membrane Glycoprotein IIbIBA 02/2016 - 05/2007
6	eicosapentaenoic acid ethyl esterIBA 01/2022 - 01/2020
6	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 01/2022 - 12/2009
6	CholesterolIBA 01/2022 - 04/2009
6	Warfarin (Coumadin)FDA LinkGeneric 11/2019 - 06/2012
6	Troponin IIBA 01/2016 - 04/2002
5	CSL112IBA 01/2022 - 10/2016
5	LipidsIBA 01/2022 - 04/2009
5	Apolipoprotein A-I (Apolipoprotein A1)IBA 01/2022 - 10/2016
5	Purinergic P2Y Receptor AntagonistsIBA 08/2020 - 12/2009
5	Platelet Membrane GlycoproteinsIBA 01/2020 - 06/2004
5	Factor Xa (Coagulation Factor Xa)IBA 01/2019 - 01/2012
4	Troponin T (Troponin T1)IBA 06/2022 - 07/2002
4	LDL CholesterolIBA 03/2022 - 12/2018
4	arginyl- 2,'6'- dimethyltyrosyl- lysyl- phenylalaninamideIBA 12/2019 - 04/2013
4	Streptokinase FDA Link 01/2018 - 12/2009
4	thienopyridineIBA 05/2015 - 11/2007

Therapy/Procedure

152	Percutaneous Coronary Intervention 06/2022 - 04/2002
145	Therapeutics 11/2022 - 02/2002
72	Stents 11/2022 - 01/2002
32	Thrombolytic Therapy 11/2012 - 10/2002
24	Coronary Artery Bypass (Coronary Artery Bypass Surgery) 01/2020 - 07/2002
12	Patient Readmission 11/2019 - 04/2004
10	Drug-Eluting Stents 11/2022 - 06/2003
9	Thrombectomy 10/2016 - 03/2011
6	Blood Transfusion (Blood Transfusions) 01/2018 - 06/2007
5	Drug Therapy (Chemotherapy) 01/2021 - 04/2007
4	Secondary Prevention 03/2019 - 03/2007
4	Catheters 11/2018 - 07/2002
4	Length of Stay 01/2016 - 06/2002